Huang Guo, deputy director of the National Medical Products Administration, said in Shanghai on the 16th that the National Medical Products Administration has approved a total of 136 innovative drugs for marketing since its establishment in 2018.
Huang Guo made the above statement at the 2023 Shanghai International Biomedical Industry Week, which opened on the 16th. Huang Guo said that biomedicine is one of the three leading industries focused on development in Shanghai. In recent years, my country's biomedicine industry has entered an unprecedented fast lane.
Huang Guo said that to promote the high-quality development of the biopharmaceutical industry, we must create a good environment for industrial innovation, accelerate the launch of new and good drugs, and enhance the health and well-being of the people. In the next step, we must continue to deepen the reform of the review and approval system, focusing on the development of urgently needed clinical drugs such as major diseases, rare diseases, and children's drugs; continue to play the special role of the Yangtze River Delta Branch Center for Drug Review and Inspection of the State Food and Drug Administration, and fully support the creation of The Yangtze River Delta biopharmaceutical industry cluster centered in Shanghai; actively participates in global drug safety governance and the improvement of drug production, R&D and supply chains, and continuously improves the international level and international influence of China's pharmaceutical development.
From October 16th to 20th, the 2023 Shanghai International Biopharmaceutical Industry Week with the theme of "Building a Vibrant Future Together" was officially held to help Shanghai accelerate the construction of a biopharmaceutical industry innovation highland and a world-class biopharmaceutical industry with global influence. Biomedical industry cluster.
